Here are five facts:
1. The company’s shares opened at $46.49 on Jan. 26.
2. On Jan. 12, Canaccord Genuity analysts rated NuVasive as “buy.”
3. NuVasive has a P/E ratio of 38.08.
4. The company’s 12-month low is $41.52 and its 12-month high is $56.61.
5. The 50-day moving average is $51.29 and the 200-day moving average is $51.93.
More articles on devices:
C2 Therapeutics expands leadership team — 4 highlights
St. Jude Medical stock dips by 0.2%: 5 things to know
SpineGuard names Steve McAdoo VP: 3 notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
